Nantahala Capital Management, LLC Aeglea Bio Therapeutics, Inc. Transaction History

Nantahala Capital Management, LLC

$1.68 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.11 - $0.46 $50,250 - $210,136	-456,819 Reduced 10.02%	4,101,193 $1.85 Million
Q1 2023 May 15, 2023	SELL	$0.29 - $0.61 $15,454 - $32,506	-53,290 Reduced 1.16%	4,558,012 $1.32 Million
Q4 2022 Feb 14, 2023	BUY	$0.35 - $1.54 $315,183 - $1.39 Million	900,524 Added 24.27%	4,611,302 $2.08 Million
Q3 2022 Nov 10, 2022	SELL	$0.38 - $0.81 $63,282 - $134,891	-166,533 Reduced 4.3%	3,710,778 $1.95 Million
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $338,359 - $1.8 Million	676,718 Added 21.14%	3,877,311 $1.96 Million
Q1 2022 May 13, 2022	BUY	$1.87 - $4.77 $723,751 - $1.85 Million	387,033 Added 13.76%	3,200,593 $7.36 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $4.54 Million - $10.9 Million	1,296,605 Added 85.47%	2,813,560 $13.4 Million
Q3 2021 Nov 15, 2021	SELL	$6.03 - $7.95 $965,288 - $1.27 Million	-160,081 Reduced 9.55%	1,516,955 $12.1 Million
Q2 2021 Aug 16, 2021	SELL	$6.32 - $8.38 $221,528 - $293,735	-35,052 Reduced 2.05%	1,677,036 $11.7 Million
Q1 2021 May 14, 2021	SELL	$6.76 - $8.57 $1.77 Million - $2.25 Million	-262,214 Reduced 13.28%	1,712,088 $13.6 Million
Q4 2020 Feb 16, 2021	SELL	$7.02 - $9.83 $8.07 Million - $11.3 Million	-1,149,128 Reduced 36.79%	1,974,302 $15.5 Million
Q3 2020 Nov 16, 2020	SELL	$6.51 - $9.33 $529,914 - $759,462	-81,400 Reduced 2.54%	3,123,430 $22.1 Million
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $1.41 Million - $3.89 Million	352,570 Added 12.36%	3,204,830 $29.6 Million
Q2 2019 Aug 14, 2019	BUY	$6.1 - $8.78 $1.22 Million - $1.76 Million	200,000 Added 7.54%	2,852,260 $19.5 Million
Q1 2019 May 15, 2019	BUY	$7.6 - $9.4 $950,000 - $1.18 Million	125,000 Added 4.95%	2,652,260 $21.4 Million
Q3 2018 Nov 14, 2018	BUY	$8.24 - $11.0 $2.59 Million - $3.46 Million	314,208 Added 14.2%	2,527,260 $24.2 Million
Q2 2018 Aug 14, 2018	BUY	$7.87 - $10.89 $2.9 Million - $4.01 Million	368,379 Added 19.97%	2,213,052 $23.4 Million
Q4 2017 Feb 14, 2018	BUY	$4.0 - $5.98 $967,080 - $1.45 Million	241,770 Added 15.08%	1,844,673 $9.98 Million
Q3 2017 Nov 14, 2017	BUY	$2.91 - $4.93 $4.66 Million - $7.9 Million	1,602,903	1,602,903 $7.9 Million

Others Institutions Holding AGLE

# of Institutions

Shares Held

241K

Call Options Held

Put Options Held

Abingworth LLP London, X0

241K
Shares

$6.65 Million
0.04% of portfolio

View Full List

About Aeglea BioTherapeutics, Inc.

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

More about AGLE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.

Account